NCT05409235: A reported trial by OcuTerra Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05409235 |
|---|---|
| Title | OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 29, 2022 |
| Completion date | Dec. 29, 2023 |
| Required reporting date | Dec. 28, 2024, midnight |
| Actual reporting date | April 29, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |